Answers are grounded in this paper and cite their sources.
qBRA application within this sample of life sciences companies was widespread, but concentrated in a small fraction of assets. Its use was primarily for internal decision-making or regulatory submissions. While some companies had plans to build further capacity in this area, others were waiting for further regulatory guidance before doing so.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: